Tributyrin supplement for people with progressive supranuclear palsy, tested through remote visits
Tests the safety and tolerability of tributyrin in people with progressive supranuclear palsy.
Key facts
- Who runs it
- Prabesh Kanel
- Where
- Ann Arbor, United StatesSee the site
- Trial code
- Registry title
- Tributyrin for Progressive Supranuclear Palsy (PSP): Virtual Trial
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 15 people, planned
- Started
- 1 Oct 2026
- Expected to end
- May 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Tributyrin
- Placebo
- Record updated
- 5 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 45 and over with progressive supranuclear palsy (PSP-Richardson syndrome), who can take part in video visits and have a caregiver.
- Age
- 45 years and over
- Sex
- Men and women can join.
- Disease stage
- Diagnosis of PSP-Richardson syndrome by Movement Disorder Society criteria, including vertical supranuclear gaze palsy and repeated unprovoked falls OR a tendency to fall on the pull test within 3 years.
- Earlier treatment
- People who regularly use typical anti-cholinergic drugs cannot join.
Main reasons for not taking part
- Recent significant, uncontrolled GI disease, such as gastroesophageal reflux disease or colorectal cancer
- Significant metabolic or uncontrolled medical comorbidity
- Women of child-bearing potential, or who are pregnant and/or nursing
- Suicidal ideation (answer of 2 or 3 on question 9 of the Beck Depression Inventory)
- No internet and webcam for virtual visits, or no caregiver
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Male or Female, age 45 years and over
- Diagnosis of PSP-Richardson syndrome (RS) based on Movement Disorder Society (MDS) Criteria, including; Vertical supranuclear gaze palsy; Repeated unprovoked falls OR tendency to fall on the pull test within 3 years
- Access to the internet and webcam for virtual visits
- Presence of a caregiver
Who cannot take part
- Regular use of typical anti-cholinergic drugs
- Recent history of significant, uncontrolled GI disease such as Gastroesophageal reflux disease, colorectal cancer
- Any other condition or criterion that, in the opinion of the investigators, would preclude safe and meaningful participation in the study
- Significant metabolic or uncontrolled medical comorbidity
- Women of child-bearing potential, or who are pregnant and/or nursing
- Suicidal ideation, as indicated by a response of 2 or 3 on question 9 of the Beck Depression Inventory
Where in United States
- Domino's FarmsAnn Arbor, United StatesContact: Nathan AlexanderTaking people
About the trial
What the trial wants to find out
This research is studying a supplement called tributyrin in people with Progressive Supranuclear Palsy (PSP) to learn about its safety and tolerability as a potential treatment. The goal of this research study is to see if a similar supplementation regimen and virtual testing is feasible for people with PSP.
The 2 groups in the trial
- TributyrinTreatment being tested
Participants will take 500mg three times a day (TID) tributyrin supplement for 90 days +/- 7 days.
- PlaceboPlacebo, for comparison
Participants will take 500mg placebo for 90 days +/- 7 days.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Tributyrin for PSP: Phase 1b Virtual Trial - Feasibility Study
- Plain-language title
- Tributyrin supplement for people with progressive supranuclear palsy, tested through remote visitsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Record updated
- 5 November 2026